EU signature trades with Bavarian Scandinavian for supply of 110,000 monkeypox vaccine

Brussels — The European Union signed an agreement with Bavarian Nordic on Tuesday to supply about 110,000 doses of vaccine against monkey pox, the EU Commission and the company said.

Vaccines will be purchased with EU funding and delivered to EU states, said EU health commissioner Stella Kiriakides. Doses are provided in proportion to the population, starting in the states with the most urgent needs.

Delivery will begin immediately and will be completed within a few months, the company said. After trading with the EU and other small deals on vaccine supply, we raised our outlook for this year’s results.

According to the European Commission, about 900 cases of monkey pox have been reported in 19 EU countries, as well as in Norway and Iceland, and are entitled to doses even though they are not EU member states.

The Danish biotechnology Bavarian Nordic vaccine, known in Europe as Imvanex and in the United States as Jynneos, has been approved for natural pox.

According to the EU Commission, a vaccine against monkeypox has not yet been approved in the EU.

“But the small pox vaccine protects people from monkey pox because the virus is so closely associated with the small pox virus,” the commission said.

According to the European Commission, EU drug regulators are currently in talks with Bayern Nordic on expedited approval of the vaccine for Monkey Pox.

Some EU member states, including Germany and Spain, have already ordered their own monkeypox vaccine.

Francesco Guarascio, Anna Ringstrom, Bart Meijer